About this trial
The main objective of this scientific study is to evaluate the short-term (1-year) survival and success rates of dental implants restored immediately compared to implants restored after a three-month healing period.
The total duration of the study is 12 months following implant placement, during which clinical and radiographic evaluations will be carried out at different follow-up time points.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Men and women between 18 and 70 years of age.
Ability to read, understand, and sign the informed consent form.
Need for placement of one or more implants for fixed prosthetic rehabilitation in either arch.
Insertion torque ≥ 35 Ncm (lower values will be excluded from the study).
Disqualifiers
Inability to attend follow-up appointments.
Systemic contraindications to oral surgery (ASA III or IV).
Pregnancy or breastfeeding.
Chronic use of corticosteroids, bisphosphonates, or RANKL inhibitors within the last year.
Trial design
Parallel
Treatments tested in this trial
Control Group
DevicePlacement of a Lynx CONNECT dental implant following the standard surgical protocol. Attachment of a healing abutment (\~1 mm above the soft tissue) instead of immediate restoration. Healing abutment remains in place for 3 months until final impression is taken for definitive crown fabrication. Post-operative care: antibiotics (amoxicillin 1.5 g/day or clindamycin 900 mg/day for 3 days), chlorhexidine rinse 0.2%, ibuprofen up to 1.2 g/day. Follow-up visits at 10-14 days, 3 months, 6 months, and 12 months for clinical and radiographic assessment.
Test group - Implant restoration with a temporary crown
DevicePlacement of a Lynx CONNECT dental implant following the standard surgical protocol. Immediate attachment of a temporary screw-retained crown on the implant abutment (CONNECT). Occlusion adjusted to avoid full contact with antagonist teeth. Temporary crown will remain for 3 months until final impression is taken for definitive crown fabrication. Post-operative care: antibiotics (amoxicillin 1.5 g/day or clindamycin 900 mg/day for 3 days), chlorhexidine rinse 0.2%, ibuprofen up to 1.2 g/day. Follow-up visits at 10-14 days, 3 months, 6 months, and 12 months for clinical and radiographic assessment.
Treatment groups
Trial outcomes
Primary outcomes
Implant survival rate
Any implant removed after placement will be considered a failure, whatever the reason. Implant survival will be evaluated clinically and radiographically by counting the remaining implants. The implant survival rate will be calculated by dividing the number of non-failures by the number of installed implants. In addition, the implant survival rate will be calculated at the patient level and on an implant level.
Secondary outcomes
Implant success rate
Defined as probing depth (PD) \< 6 mm together with the absence of bleeding or suppuration on probing and a radiographic marginal bone level (MBL) \< 1.5 mm.
Prosthetic success
Defined as the presence of the definitive prosthesis with patient satisfaction and without complications, including and not limited to fracture/chipping, screw loosening, and prosthesis mobility.
Implant insertion torque
Using a motor device or a torque-controlled hand rachet
Marginal bone changes
Measured on parallel intra-oral radiographs using computer software. Marginal bone level alterations will be determined from radiographs and expressed as the distance from the implant reference point (shoulder) to the most coronal bone-to-implant contact on the mesial and distal side of the implant.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Universidade do Porto
Lead sponsor
MIS Implants Technologies Ltd
Collaborator
This trial is not recruiting at the moment. You can still explore other options: